Raghava Competitors

We are a pioneering transatlantic TechBio company that aims to transform health through the power of genomics. The company was formed in 2014 by four world-leading statistical and human geneticists at the University of Oxford, including Professor Sir Peter Donnelly and Professor Gil McVean. We use large-scale genetic information to realise preventative medicine and improve drug discovery. We're a world-leader in genomic prevention: a paradigm-changing approach to sustainable healthcare which for the first time allows reliable, personalised estimates of risk for all the common diseases and cancers, well ahead of disease manifestation, allowing accurate and early interventions and tailored screening. Our proprietary algorithms and databases offer something no competitor can: the ability to accurately link minute variation across the entire genome to changes in thousands of biological measurements and disease outcomes, to generate population-level insights for healthcare systems, individual-level insights for clinicians about the risk of common diseases, and new understanding of disease processes. We work with leading life sciences and biotech companies, including Novo Nordisk and Vertex. Our team is a multi-disciplinary group of world experts focused on finding powerful and creative solutions for bringing subject-leading science to as wide an audience as possible, and, in doing so, offer the chance of transforming lives around the world. The workforce is highly qualified and consists of over 150 people, including world-leading genomic scientists, computational biologists, statisticians, software engineers, product developers, data scientists and commercial strategists. We are headquartered in Oxford, with offices in Cambridge (UK), London (UK), and North Carolina (US), with labs in Massachusetts (US).

BioIntelligence Technologies inc. design and commercialize intelligent monitoring instruments with embedded analytic package to accelerate bioprocess development and maximize production profitability. Our instruments perform real-time analysis as well as prediction over time of both biologic variables and financial indicators. Among the benefits of using these products, users can: *increase revenues by taking early decisions and actions based on predicted final product yields; *reduce costs by quickly identifying non-profitable operations and non-profitable batches; *save time using personalized dashboards and the real-time automatic reporting modules. Our clients are biopharmaceutics, biocosmetics, food and supplement companies, environmental process users, bioprocess development centers, research & scale-up groups as well as academic groups. Real-time knowledge of how kinetics, actions and recipe affect revenues and costs makes the ROI of such real-time intelligent monitoring system very fast and lucrative. Go to biointelligence.com to see our products proudly made for bio people.

cellomics.com is a company that operates in the Biotechnology industry. It employs 11-20 people and has $5M-$10M of revenue.